Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. [electronic resource]
Producer: 20130822Description: 665-70 p. digitalISSN:- 1879-355X
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cetuximab
- Dose Fractionation, Radiation
- Esophagitis -- etiology
- Esophagus -- radiation effects
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms -- drug therapy
- Lymphatic Irradiation -- methods
- Male
- Maximum Tolerated Dose
- Middle Aged
- Organs at Risk -- radiation effects
- Prospective Studies
- Proton Therapy -- adverse effects
- Radiation Pneumonitis -- etiology
- Relative Biological Effectiveness
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.